STOCK TITAN

XORTX Announces Research Coverage Initiated by A.G.P./Alliance Global Partners

Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary

XORTX Therapeutics Inc. (NASDAQ: XRTX) announced that A.G.P./Alliance Global Partners has initiated research coverage on the company. This marks a significant milestone for XORTX, which is developing innovative therapies for progressive kidney disease, including XRx-008 for Autosomal Dominant Polycystic Kidney Disease and XRx-101 for COVID-19. The coverage report by James Molloy, a senior biotechnology analyst, emphasizes XORTX’s commitment to addressing critical health concerns. It can be accessed online or via direct contact with A.G.P.

Positive
  • Initiation of research coverage by A.G.P./Alliance Global Partners may enhance investor visibility.
  • XORTX is advancing its clinical pipeline with products targeting significant health issues.
Negative
  • None.

CALGARY, Alberta, Dec. 09, 2021 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a pharmaceutical therapeutics company focused on developing innovative therapies to treat progressive kidney disease, announced today that James Molloy, Senior Biotechnology Analyst at A.G.P./Alliance Global Partners, has initiated research coverage on XORTX.

The report is available online at the following link (A.G.P. / XRTX: Targeting kidney diseases) or can be obtained by contacting A.G.P./Alliance Global Partners at jmolloy@allianceg.com.

Please note that any opinions, estimates, or forecasts regarding the performance of XORTX and its management made by A.G.P./Alliance Global Partners are theirs alone and do not represent the opinions, estimates, or forecasts of XORTX or its management.

About XORTX Therapeutics Inc.

XORTX Therapeutics Inc. is a pharmaceutical company with two clinically advanced products in development – XRx-008 for Autosomal Dominant Polycystic Kidney Disease (ADPKD), XRx-101 for Coronavirus / COVID-19 infection and XRx-225 is a pre-clinical stage program for Type 2 Diabetic Nephropathy (T2DN). XORTX is working to advance its clinical development stage products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid. At XORTX Therapeutics, we are dedicated to developing medications to improve the quality of life and future health of patients. Additional information on XORTX Therapeutics is available at www.xortx.com.

About A.G.P./Alliance Global Partners

Headquartered in New York City, A.G.P./Alliance Global Partners is an institutional investment banking firm with a strong sales/trading presence, in addition to its research and investment banking arms.

For further information, please contact:
Allen Davidoff, CEONick Rigopulos, Director of Communications
adavidoff@xortx.com or +1 403 455 7727nick@alpineequityadv.com  or +1 617 901 0785

The TSX Venture Exchange and Nasdaq have neither approved nor disapproved the contents of this news release. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.

Forward Looking Statements

This press release contains express or implied forward-looking statements pursuant to Canadian and U.S. Federal securities laws. These forward-looking statements and their implications are based on the current expectations of the management of XORTX only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Except as otherwise required by law, XORTX undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties affecting XORTX is contained in the Company’s Management’s Discussion and Analysis for the interim period ended June 30, 2020 filed on the Company’s SEDAR profile (www.sedar.com) and under the heading “Risk Factors” in XORTX’s Registration Statement on Form F-1 filed with the Securities and Exchange Commission (“SEC”) available on the SEC's website, www.sec.gov.


FAQ

What is the significance of A.G.P. initiating coverage on XORTX (XRTX)?

The initiation of coverage by A.G.P./Alliance Global Partners may improve visibility and credibility for investors looking at XORTX.

What therapies is XORTX Therapeutics developing?

XORTX is developing XRx-008 for Autosomal Dominant Polycystic Kidney Disease, XRx-101 for COVID-19, and XRx-225 for Type 2 Diabetic Nephropathy.

Who is the analyst providing coverage on XORTX?

James Molloy, Senior Biotechnology Analyst at A.G.P./Alliance Global Partners, is providing coverage on XORTX.

Where can I find the research report on XORTX?

The report can be accessed online through A.G.P.'s website or by contacting them directly.

XORTX Therapeutics Inc.

NASDAQ:XRTX

XRTX Rankings

XRTX Latest News

XRTX Stock Data

4.61M
3.22M
3.35%
6.37%
0.01%
Biotechnology
Healthcare
Link
United States of America
Alberta Beach